In this regard, reports indicate that chronic treatment with FLX (a drug used to counteract depressive symptoms, belonging to the SSRI family) desensitizes 5-HT1A heteroreceptors in the hypothalamus, an effect dependent on serotonergic innervation.[47] Preclinical and clinical studies – imaging and postmortem – have demonstrated the correlation of the expression, activation, and signaling of 5-HT1A and 5-HT2A receptors with depressive disorder.[25,35,48–50]. Here, HTR1A is linked to depressive disorder.